<DOC>
	<DOCNO>NCT02791386</DOCNO>
	<brief_summary>The purpose study describe current rescue treatment pattern nucleot ( ) ide analogue ( NA ) resistance assess real-world treatment outcomes health resource utilization rescue treatment drug resistance clinical cohort Chinese patient chronic hepatitis B ( CHB ) .</brief_summary>
	<brief_title>Rescue Treatment Pattern , Drug Resistance Recurrence , Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B Drug Resistance Nucleot ( ) Ide Analogue Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>CHB patient drug resistance confirm hepatitis B virus ( HBV ) gene mutation virological breakthrough Patient receive rescue treatment drug resistance previous NA therapy CHB Patient regularly follow least every 6 month drug resistance tertiary liver clinic SXH Patient diagnosis hepatocellular carcinoma , decompensated cirrhosis , and/or liver transplantation prior development drug resistance NA therapy CHB Patient coinfection hepatitis C virus , hepatitis D virus , and/or human immunodeficiency virus Patient life expectancy le 6 month date first laboratory test indicate drug resistance Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>